Conor Fearon (@FearonConor) profile picture

Neurologist | Movement Disorders

Joined February 2013
Photo by Conor Fearon (@FearonConor)Photo by Conor Fearon (@FearonConor)
Conor Fearon retweeted
What constitutes the loss of motivation and interest in daily activities (apathy) in PD? Can we distinguish it from overlapping non-motor symptoms? Does dopamine replacement (ON or OFF) make a difference? Our effort now in @MDCP Link to full text: movementdisorders.onlinelibr…
9
22
1,439
Conor Fearon retweeted
Big challenge in Parkinson’s is that synuclein seeding assays can be positive across many diseases. Nice plenary this morning showing how this group uses synuclein seeding + 4 R TAU + NFL to sort this out using a multi-modal biomarkers approach. This is one such approach used at the University of Toronto and presented today at the World Parkinson Congress.
1
17
68
3,578
Conor Fearon retweeted
Cullinane et al. identify three subtypes of progressive supranuclear palsy with different progression patterns and show that sex, genetic variation, and co-pathology influence tau distribution and clinical phenotype. shorturl.at/1cZcy
11
47
3,733
We are very proud of this achievement! Congratulations to @LucaMarsili1, @AMahajanMD, @AlbertoEspay, and the other faculty and co-authors of this award-winning manuscript! 🎉🧠
We’re excited to announce the winning article of this year’s Neurology Resident & Fellow Section Writing Award: “Clinical Reasoning: Juvenile-Onset Dopa-Responsive Dystonia—Until It Isn’t.” 👏 Join us in celebrating the outstanding authors: hubs.la/Q046P4Hn0 #NeurologyRF
1
4
18
1,354
Conor Fearon retweeted
Genetic differentials of Rapid onset Dystonia Parkinsonism: ATP1A3, SLC19A3 (BTBGD), PRKRA @FearonConor @MDJ_Journal #neurotwitter doi.org/10.1002/mds.70286
1
6
20
952
Did you know AD pathology also impacts PD and related disorders? This review underscores the impact of aβ and tau co-pathology on clinical progression and heterogeneity in PD and atypical parkinsonism, emphasizing the value of biomarker approaches. 301.tv/HYSwt
1
1
101
Conor Fearon retweeted
Several MDS rating scales now have official versions within REDCap, thanks to efforts by the Electronic COA Committee to promote compliance and uniformity in clinical research. @MDJ_Journal movementdisorders.onlinelibr…
1
2
6
484
Conor Fearon retweeted
The University of Cincinnati Movement disorders fellowship is well represented at the #PASCongress! Super proud.
1
4
1
41
2,761
Superb presentation on the future of #ataxia treatment by @neurosrq today at #PASCongress @movedisorder
1
5
19
1,145
Dementia with Lewy bodies: a practical guide to clinical diagnosis and management pn.bmj.com/content/26/1/4
2
53
163
9,736
Our group just published the First Saudi data on fatigue in Parkinson’s disease: • 61% had significant fatigue (FSS ≥4) • Fatigue linked to non-motor symptoms • Higher risk with low physical activity and low water intake link.springer.com/article/10… #ParkinsonsDisease #Fatigue
1
10
1,639
Recurrent “delirium”, normal scans, fluctuating cognition - sound familiar? Our recent review shows why dementia with Lewy bodies is often hiding in plain sight, and how to recognise it early in clinic and on the ward. 🔓 Open access: pn.bmj.com/content/26/1/4 #Neurology #OpenAccess #FOAMed
15
50
3,617
Conor Fearon retweeted
After rewatching Home Alone, I couldn’t stop wondering: how plausible is the oversleep that leaves Kevin behind? So I wrote a tiny paper and ran the numbers. Merry Christmas! 🎄
420
3,423
577
21,462
1,654,631
Foslevodopa infusion in the real world has shown promise for Parkinson's, however we must pay attention to any emergent neuropsychiatric symptoms. Continuous subcutaneous infusion refers to medication delivered under the skin at a steady rate to smooth out motor fluctuations. This research letter provides important insights into safety signals that may emerge when folks start and adjust this therapy at home. Maeve Bradley and colleagues describe in Movement Disorders Clinical Practice their extended real world experience w/ foslevodopa foscarbidopa using an outpatient titration protocol. Key Points: - Outpatient initiation was feasible, however dose optimization still required several weeks and infusion rates increased by an average of 35% from baseline. -Neuropsychiatric complications were more frequent w/ hallucinations emerging in 21 percent of patients and frequently appearing weeks after initiation. - Discontinuation rates were similar to inpatient programs, however reasons differed and included neuropsychiatric symptoms, infusion site issues and lack of effectiveness. My take: We will need to provide guidance on when to employ pump therapies in Parkinson's and what to do if neuropsychiatric symptoms emerge. Real-world data is really important to this effort. Here are 5 points that resonated w/ me: 1- Expect individualized dosing because stable infusion rates usually take weeks to achieve and will require close follow up. 2- Watch for delayed hallucinations because these symptoms may appear long after the first few days of treatment and require rapid adjustment. 3- Understand the role of past psychosis since a history of hallucinations may increase risk, however does not perfectly predict who will struggle. 4- Rely on your care team because trained nurses visiting at home can safely guide adjustments and keep therapy on track. 5- Recognize when to stop because some folks will discontinue due to neuropsychiatric issues or skin reactions, and switching therapies may be the best option for some folks. movementdisorders.onlinelibr… @ParkinsonDotOrg @FixelInstitute @PdAvengers @ACPIMPhysicians @movedisorder
2
10
2
45
5,541
It was wonderful having you in Dublin. A masterclass in itself! Your grand rounds performance was a tour de force. We’ll have to find even more complex cases next year!
Thank you, @FearonConor⁩ for your friendship and for leading with Tim Lynch and Dublin team a splendid Irish PD & Movement Disorders⁩ Master Class. I learned from the many cases presented and the Grand Rounds. Eternally grateful. 🙏🏻❤️
1
9
1,380
Another reason to fly to Dublin today: sharing similarly rainy conditions with Cincinnati. That’s a connection! ⁦🙏🏻@FearonConor⁩?
1
1
7
1,322
Excited to share our new work in @NatureComms guided by @GMI_Canada C.Gorodetsky A.Fasano @LindseyMVogt @KarimMithaniMD! SD is a distinct state w/ beta-band activity, paving the way for biomarkers track clinical states/aDBS @SickKidsNews @UofTNeurology nature.com/articles/s41467-0…
1
8
1
21
3,860
Is sleep affected in dystonia? Do pain and psychiatric burden impact it? Does botulinum toxin improve it? Our analysis of sleep concerns in over 1000 individuals with cervical dystonia, and longitudinal response pattern to botulinum toxin is now online. movementdisorders.onlinelibr…
6
21
1,332
Grateful to join the #MDSCongress in Hawaii. Great opportunity to share my work on ventriculomegaly & gait impairment, and a rare SQSTM1-linked FTD with parkinsonism. Inspiring discussions and amazing networking! #MDSCongress #Neurology#MovementDisorders
1
1
13
750